Thursday, 24 January 2019

Anthony Hughes' s stories

Sort by: Newest firstOldest firstA-ZZ-A

  • Infor eyes US IPO in 12-24 months

    Equities | 18 January 2019

    Infor, the New York-based enterprise software provider led by former Oracle president Charles Phillips, has set its sights on an IPO, one of a long list of sponsor/leverage-backed software companies that could come to public markets in the next few years.

  • Securities and Exchange Commission logo

    Washington shutdown adds to US IPO woes

    Top News | 04 January 2019

    The US government shutdown is creating another complication for US IPO candidates already negotiating treacherous market conditions, potentially causing delays that could ripple through the 2019 deal backlog.

  • Stealth BioTherapeutics ditches HK for US IPO

    Stealth reveals Nasdaq IPO plans

    Ticker | 29 December 2018

    Stealth BioTherapeutics, a clinical-stage developer of new drugs to treat mitochondrial dysfunction, filed publicly for a US$86.3m Nasdaq IPO late Friday, making it one of four additions to the biotech new issue calendar in the past week.

  • Futu Holdings files for US$300m Nasdaq IPO

    Futu prepares to execute US$300m US IPO

    Ticker | 28 December 2018

    Tencent-backed Futu, a fast-growing Hong Kong/China-based online stockbroker, could become one of the first big Asia-to-US listings in the new year, publicly filing late Friday for a US$300m Nasdaq IPO.

  • T cells poised to become 2019 biotech IPO theme

    Ticker | 28 December 2018

    TCR² Therapeutics became the second T cell-focused biotech in as many days to file for an IPO, registering with the SEC for a US$100m Nasdaq listing that could price early in the new year.

  • Harpoon strikes for Nasdaq IPO

    Ticker | 28 December 2018

    Harpoon Therapeutics, a clinical-stage biotech developing a new class of “T cell engagers” to treat cancer, filed late Thursday for a US$86.25m Nasdaq IPO.

  • Gossamer weaves way onto early 2019 IPO calendar

    Ticker | 22 December 2018

    Gossamer Bio, a San Diego-based clinical-stage biotech focused on immunology, inflammation and oncology, filed publicly late Friday for a US$264.5m Nasdaq IPO.

  • Benefitfocus seeks US$200m from CB financing

    Ticker | 20 December 2018

    Benefits management software provider Benefitfocus suffered a steep share price fall in Thursday’s session as it marketed a US$200m convertible bond financing.

  • Stock slump casts doubt on Colfax stock sale

    Ticker | 20 December 2018

    A 25%-plus slump in the stock price of industrial equipment maker Colfax has complicated plans to raise US$500m-$700m in equity or equity-linked securities to help fund the pending US$3.15bn cash acquisition of orthopedic device maker DJO Global. But management insists its plans have not changed.

  • MOVES-Mizuho appoints new US ECM head

    Ticker | 20 December 2018

    Josh Weismer has joined Mizuho Americas as head of US equity capital markets, the bank said in a statement today.

Show  10 per page20 per page50 per page